Amgen gets FDA approval for potential billion-dollar drug
Thousand Oaks-based Amgen won approval from the U.S. Food and Drug Administration on May 28 for its latest oral drug treatment, Lumakras, potentially adding another huge market for one of the largest biotech firms in the world. According to the Wall Street Journal, Amgen will charge $17,900 a month for the drug and analyst think Read More →
Public health meets private sector with Charity Dean’s new venture
Months into the COVID-19 pandemic, Dr. Charity Dean realized a harsh reality. She was then assistant director of the California Department of Public Health, and she knew the state and nation were literally in a do-or-die situation. “As a local health officer, I learned painfully that no one is coming to save me,” Dean, who Read More →
Cure reports net loss, rising revenue in Q1
Oxnard-based Cure Pharmaceutical saw another spike in revenue in the first quarter of 2021, but net losses also continued to grow. Cure had $1.5 million in revenue in the quarter ended March 31, up 400% from the first quarter of 2020, according to the company’s earnings report, released May 17. The bulk of that growth Read More →
Direct Relief comes to India’s aid during COVID crisis
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Revenue up at MannKind, but losses mount
Westlake Village-based biotech company MannKind saw a slight bump in revenue in the first quarter thanks to its product Afrezza, but net losses continued to climb. MannKind released its earnings after the markets closed on May 12. It ended the day down 8.6% and regained 0.25% on May 13, to close at $4.03. MannKind, which Read More →
Westlake Village BioPartners makes big bet on gene therapy with Capsida
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen planning apartments on its land in Thousand Oaks
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
